Synthesis and antiproliferative activity of (2R,3R)-disubstituted tetrahydropyrans. Part 2: Effect of side chain homologation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 780-783

  Carrillo, Romen ^a   León, Leticia G ^a,b   Martín, Tomás ^a,c   Martín, Víctor S ^a   Padrón, José M ^a,b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b Madrid Spain   (Spain)

^c INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

Author keywords

Anticancer drugs; Cyclic ethers; Marine products; Solid tumors; Structure activity relationship

Indexed keywords

TETRAHYDROPYRAN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; COLON CANCER; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; OVARY CANCER; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHYSICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; PYRANS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846214455     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.066     Document Type: Article

References (29)

1. Mayer A.M.S., and Gustafson K.R. Eur. J. Cancer 42 (2006) 2241 and references therein
2. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Marti{dotless}́n V.S. ChemMedChem. 1 (2006) 323
3. Crisóstomo F.R.P., Padrón J.M., Marti{dotless}́n T., Villar J., and Marti{dotless}́n V.S. Eur. J. Org. Chem. (2006) 1910
4. Crisostomo F.R.P., Marti{dotless}́n T., and Marti{dotless}́n V.S. Org. Lett. 6 (2004) 565
5. Betancort J.M., Marti{dotless}́n T., Palazón J.M., and Marti{dotless}́n V.S. J. Org. Chem. 68 (2003) 3216
6. Di{dotless}́az D., Marti{dotless}́n T., and Marti{dotless}́n V.S. Org. Lett. 3 (2001) 3289
7. Garci{dotless}́a C., Marti{dotless}́n T., and Marti{dotless}́n V.S. J. Org. Chem. 66 (2001) 1420
8. Marti{dotless}́n T., and Marti{dotless}́n V.S. Tetrahedron Lett. 41 (2000) 2503
9. Marti{dotless}́n T., Soler M.A., Betancort J.M., and Marti{dotless}́n V.S. J. Org. Chem. 62 (1997) 1570
10. Rami{dotless}́rez M.A., Padrón J.M., Palazón J.M., and Marti{dotless}́n V.S. J. Org. Chem. 62 (1997) 4584
11. Betancort J.M., Marti{dotless}́n V.S., Padrón J.M., Palazón J.M., Rami{dotless}́rez M.A., and Soler M.A. J. Org. Chem. 62 (1997) 4570
12. Donadel O.J., Marti{dotless}́n T., Marti{dotless}́n V.S., Villar J., and Padrón J.M. Bioorg. Med. Chem. Lett. 15 (2005) 3536
13. Padrón J.M., Donadel O.J., León L.G., Marti{dotless}́n T., and Marti{dotless}́n V.S. Lett. Drug Des. Discov. 3 (2006) 29
14. Carrillo R., León L.G., Marti{dotless}́n T., Marti{dotless}́n V.S., and Padrón J.M. Bioorg. Med. Chem. Lett. 16 (2006) 10.1016/j.bmcl.2006.08.094
15. Crisóstomo F.R.P., Carrillo R., León L.G., Marti{dotless}́n T., Padrón J.M., and Marti{dotless}́n V.S. J. Org. Chem. 71 (2006) 2339
16. Snatzke G., Raza Z., Habus I., and Sunjic V. Carbohydr. Res. 182 (1988) 179
17. Carrillo R., Marti{dotless}́n V.S., and Marti{dotless}́n T. Tetrahedron Lett. 45 (2004) 5215
18. Carrillo R., Marti{dotless}́n V.S., López M., and Marti{dotless}́n T. Tetrahedron 61 (2005) 8177
19. Isobe T., and Ishikawa T. J. Org. Chem. 64 (1999) 5832
20. Isobe T., and Ishikawa T. J. Org. Chem. 64 (1999) 6984
21. Isobe T., and Ishikawa T. J. Org. Chem. 64 (1999) 6989
22. Fujisawa T., Mori T., Fukumoto K., and Sato T. Chem. Lett. (1982) 1891
23. Nicolaou K.C., Hwang C.K., Marron B.E., DeFrees S.A., Couladouros E.A., Abe Y., Carroll P.J., and Snyder J.P. J. Am. Chem. Soc. 112 (1990) 3040
24. Inanaga J., Baba Y., and Hanamoto T. Chem. Lett. 22 (1993) 241
25. The orientation of the phenyl group was confirmed by NOE experiments. The stereochemical control in this reaction is a consequence of the formation of the most stable cis-decaline, which has the phenyl group on an equatorial orientation.
26. Heard P.J., King P.M., Bain A.D., Hazendonk P., and Tocher D.A. J. Chem. Soc., Dalton Trans. (1999) 4495
27. 50) represent the drug concentration at which PG is +50, 0, and -50, respectively. Skehan P., Storeng P., Scudeiro D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
28. ® appeared the most accurate predictor of Clog P values. Machatha S.G., and Yalkowsky S.H. Int. J. Pharm. 294 (2005) 185
29. ® accessible via Internet (www.daylight.com/daycgi/clogp) working with the Hansch-Leo's 'fragment constant' method.